Psyence BioMed Advances Phase IIb Psilocybin Trial for Adjustment Disorder in Palliative Care
Key Insights
Psyence BioMed has successfully dosed multiple patients across two clinical sites in its Phase IIb trial evaluating nature-derived psilocybin combined with psychotherapy for Adjustment Disorder (search) in palliative care.
The multi-site, double-blind, placebo-controlled study is designed to enroll 87 patients across Australia, testing two therapeutic doses of psilocybin (10 mg or 25 mg) against a low-dose comparator (1 mg).
The company has expanded to three actively enrolling sites and anticipates topline results by year-end 2026, positioning this as the only active Australian clinical program using natural psilocybin for this indication.
Psyence Biomedical Ltd. (search) (Nasdaq: PBM) has achieved a significant clinical milestone by successfully dosing multiple patients in its ongoing Phase IIb trial evaluating nature-derived psilocybin combined with psychotherapy for Adjustment Disorder (search) in palliative care. The achievement marks a major advancement for what the company describes as the only active Australian clinical program using a natural psilocybin formulation to treat this condition.
Multi-Site Trial Expansion Accelerates Enrollment
The Phase IIb study has strategically expanded across multiple clinical sites to enhance statistical power and data reliability. Patients have been dosed across two active sites - the Empax Center (search) in Perth and the Mind Medicine Australia Clinic (search) in Melbourne - with strong operational readiness and recruitment efficiency demonstrated at both locations.
The company has also activated Paratus Clinical Research (search) in Melbourne, expanding the study to three actively enrolling sites to accelerate data collection toward topline results anticipated by year-end 2026.
"The randomization and dosing of these patients across multiple independent trial sites marks an exciting and validating milestone for Psyence BioMed," said Dr. Clive Ward-Able, Medical Director of Psyence BioMed. "With multiple sites now operational and patients progressing through screening, we are seeing strong interest and momentum. This level of engagement reinforces the importance of our work in developing psilocybin-based therapies for palliative care."
Rigorous Trial Design Meets Regulatory Standards
The multi-site, double-blind, placebo-controlled study is designed to enroll 87 patients across Australia. The trial's larger sample size, rigorous randomization, and multi-site structure have been strategically designed to meet regulatory expectations for pivotal clinical evidence.
Participants receive one of two therapeutic doses of psilocybin (10 mg or 25 mg) or a low-dose comparator (1 mg), each administered alongside structured psychotherapy. The study will assess efficacy, safety, and durability of response, with the goal of advancing psilocybin as a potential first-in-class treatment for Adjustment Disorder (search) in palliative care settings.
Addressing Unmet Mental Health Needs
The trial represents a significant step forward in addressing unmet mental health needs in palliative care settings. Psyence BioMed positions itself as a global leader in late-stage psychedelic drug development, focusing specifically on nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine.
"This pivotal moment reflects the extraordinary effort and precision required to achieve multiple patient dosing across independent clinical sites," said Jody Aufrichtig, Chief Executive Officer of Psyence BioMed. "It demonstrates not only our team's operational excellence but also the maturity of our clinical infrastructure. With a trial design that meets rigorous regulatory standards, Psyence BioMed is generating high-quality data to support future approvals, commercial readiness, and the advancement of a nature-derived psilocybin therapy for patients facing adjustment disorder (search) in palliative care."
Company Background and Market Position
Psyence Biomedical Ltd. (search) is described as one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. The company holds the distinction of being the first life sciences biotechnology company focused on developing nature-derived psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq.
The company maintains an evidence-based approach in developing what it aims to be safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders, with particular focus on palliative care applications.